Fig. 1From: A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorderFlowchart of participant stratification based on the level of high-sensitivity C-reactive protein (hs-CRP). Note: circles denote the study sessions where primary, secondary, and tertiary outcomes will be measuredBack to article page